HRT benefits and risks: asking better questions

The benefits and risks of HRT depend on the person, the hormones used, the route of administration and the reason for treatment. Age, time since menopause, medical history and whether a uterus is present all matter. A statement that “HRT is safe” or “HRT is dangerous” is too broad to guide an individual decision. [1]

The useful comparison is between realistic options for your situation: a particular regimen, another treatment, or no symptom treatment at present. This guide explains how to discuss that comparison without treating population statistics as a personal forecast or assuming that one headline settles every question.

Start with the benefit you are seeking

Systemic hormone therapy is effective for troublesome hot flushes and night sweats. It can also prevent bone loss while being used. Local vaginal oestrogen has a different purpose, addressing suitable vaginal or urinary symptoms with much lower systemic exposure. [2] [3]

Be specific about the effect you hope for. Fewer night sweats, improved sleep continuity or more comfortable intimacy can be meaningful goals. “Prevent ageing” is not a clear clinical outcome and can lead to claims that extend beyond established treatment uses.

Also identify what treatment is unlikely to solve. An independent sleep disorder, major depression, unexplained bleeding or a painful joint may need separate assessment. A favourable HRT decision does not mean every symptom should be treated by increasing hormones.

Why your starting risk matters

A treatment can have different practical implications for people with different underlying risks. A history of clotting, hormone-sensitive cancer, cardiovascular disease, liver disease or unexplained bleeding can change the choice or require specialist advice. Family history and other factors may also be relevant. [2]

Ask the clinician which parts of your history matter most and why. A family history is not always equivalent to having the condition yourself, but it should not be ignored. Similarly, age alone does not describe the whole clinical picture.

Bring accurate information rather than trying to calculate risk from an online checklist. If records from previous surgery or cancer treatment are needed, ask how to obtain them. The treatment decision should be based on the relevant details, not on assumptions made because an appointment is short.

Absolute risk and relative risk

Relative risk describes a proportional difference; absolute risk describes how many events occur in a stated population over a stated period. Both can be useful, but relative figures alone can sound more dramatic than the practical difference.

For an illustration that is not an HRT risk estimate, suppose an event occurred in four people per thousand without a treatment and six per thousand with it over the same period. The relative increase would be 50%, while the absolute increase would be two additional events per thousand. The numbers are hypothetical and should not be used to estimate your own risk.

When a clinician presents a figure, ask what outcome it describes, over how many years, in which age group and with which regimen. A comparison of different populations or time periods may not answer the question you actually face.

Breast cancer: regimen and duration matter

Breast-cancer risk is not identical for oestrogen-only and combined systemic HRT. Combined therapy is associated with increased risk, and duration is relevant. A discussion should account for the treatment being considered and the individual’s baseline risk rather than assume all hormone products have the same profile. [1]

Avoid interpreting “small increase” as no increase, or an increase as proof that a particular person will develop cancer. The aim is to put the magnitude in context with symptom burden, alternatives and preferences.

Ask whether the available evidence is specific to the proposed formulation or extrapolated from other treatments. Some comparisons remain uncertain. Routine screening should follow the appropriate local programme and personal risk assessment; a screening plan does not eliminate treatment-related risk or replace assessment of a new breast symptom.

The womb lining and progestogen

Systemic oestrogen can stimulate the endometrium, the lining of the uterus. When a uterus is present, an appropriate progestogen component is generally required to protect it. This is a central safety issue, not an optional addition intended only to regulate bleeding. [4]

If progestogen causes troublesome effects, ask about alternative regimens rather than omitting it yourself. The prescribed amount and schedule must be appropriate to the oestrogen treatment and clinical situation. A cream marketed as natural progesterone should not be assumed to provide equivalent protection.

Unexpected bleeding needs assessment according to its timing, severity and the regimen. A normal previous scan does not explain all future bleeding. The bleeding article explains why symptoms should be reported rather than suppressed through unsupervised changes in treatment.

Blood clots, stroke and route of administration

Oral and transdermal oestrogen do not have identical risk profiles. NHS guidance distinguishes the increased clot risk associated with tablets from treatment delivered through the skin. The appropriate route depends on medical history and other considerations, not simply convenience or fashion. [1]

A lower risk for one outcome does not make a patch or gel risk-free in every respect. The hormone combination, dose and individual circumstances still matter. Ask what evidence applies to the specific outcome that concerns you.

Know which symptoms require emergency care, including chest pain, sudden breathlessness, stroke-like symptoms or a painful swollen leg. Do not wait for a planned HRT review if these occur. A risk conversation should include practical safety instructions, not only statistics discussed before the first prescription.

Age, timing and early menopause

For many healthy symptomatic women younger than 60 or within 10 years of menopause, systemic hormone therapy may have a favourable benefit-risk balance. Starting later can involve a different balance, so age and timing should be interpreted with the rest of the history. [2]

This is not a rigid rule that everyone below a threshold should take HRT or everyone above it must stop. Continuing an established reviewed treatment also differs from starting for the first time after a long interval.

Early menopause and premature ovarian insufficiency need a separate discussion because replacing hormones lost unusually early can have a broader health role. Do not apply a risk figure from an older trial population directly to a younger person without explanation. Read early menopause for the distinct care questions.

Heart disease, dementia and anti-ageing claims

HRT should not be started solely as a general strategy to prevent cardiovascular disease or dementia. Symptom treatment and disease prevention are different questions, even when research explores possible relationships between hormones and later health. [5] [6]

Be cautious when a provider turns preliminary or observational findings into a guarantee of brain protection, longevity or prevention of every chronic condition. Ask whether the evidence shows a causal treatment benefit for people like you and whether major guidance recommends the proposed use.

Ordinary prevention remains important: blood-pressure management, smoking cessation, appropriate activity and treatment of relevant conditions do not become unnecessary because HRT is prescribed. Equally, choosing not to take hormones does not mean abandoning your health. The decision should address the actual indication and your priorities.

What changed in US warning labels in 2026?

On 12 February 2026, the FDA announced approved labelling changes for six menopausal hormone-therapy products, removing certain cardiovascular, breast-cancer and probable-dementia statements from their boxed warnings. The announcement described an initial group of products rather than every possible hormone preparation. [7]

A change in warning format does not mean every risk has disappeared or that every person is a suitable candidate. Consult the current label for the exact product and discuss it with the prescriber. Do not treat an older screenshot or a general news headline as the complete prescribing information.

International wording and approved indications can differ. A UK reader should not assume a US label changes local recommendations automatically, and a US reader should not use a UK product leaflet as a substitute for their own medicine’s instructions.

It can help to revisit a decision after separating medical facts from personal priorities. Two people with similar medical histories may value symptom relief, avoiding a particular adverse effect or minimising medicines differently. That does not make either preference unreasonable. Ask the clinician which options remain medically appropriate, then discuss the trade-offs within that range. Shared decision-making should not mean being left alone to interpret complex risk figures, nor should it mean having your priorities replaced by a standard prescription. [5]

A decision can also be revisited when symptoms, medical history or your preferences change; it need not be treated as a permanent commitment.

Making and reviewing the decision

Ask the clinician to summarise the expected benefit, principal risks, alternatives and uncertainties for the proposed regimen. Include practical issues such as bleeding expectations, supply, cost and follow-up. Your preferences are part of the decision, not a barrier to it.

Agree how benefit will be assessed and which adverse effects require contact. Revisit the balance if your health changes, symptoms resolve or treatment no longer helps. There is no need to interpret the first decision as permanent.

Use the appointment planner to capture unresolved questions. A well-informed HRT decision is not a verdict for or against hormones in general. It is a specific, documented choice made with an appropriately qualified clinician and reviewed as your circumstances change.